KPV in cutaneous wound healing and tissue repair — evidence extract
No eligible study has been identified for KPV in cutaneous wound healing and tissue repair. The Institute records the question as not assessed and states what would change that.
§1Evidence extract: Cutaneous wound healing and tissue repair
§1.1Question and anchor outcome
- Population
- Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.
- Intervention
- KPV, oral, topical or subcutaneous in preclinical studies
- Comparator
- As used in each contributing trial; reported per trial rather than pooled across comparator types
- Anchor outcome
- Time to complete closure
Additional outcomes the Institute extracts for this indication: Percentage area reduction; Scar assessment scale; Infection rate.
§1.2Contributing trials
No trial has been identified for KPV in cutaneous wound healing and tissue repair. No certainty rating is issued where that is so, for the reason given at §1.3.
§1.3Why no certainty rating is issued
The Institute rates certainty in a body of evidence. Where no eligible study has been identified there is no such body, and the domain-by-domain assessment used elsewhere in this series is not rendered: an inconsistency judgement requires two estimates to be inconsistent with one another, and an imprecision judgement requires an interval. Neither exists here.
The outcome is therefore recorded as not assessed. It is listed in the certainty index under that heading rather than at the lowest rating, because a rating of very low certainty says that evidence was found and is weak, and that is not what has happened.
What would change this: a controlled study in the population stated at §1.1, reporting the anchor outcome, retrievable in a form the Institute can appraise. The evidence gaps recorded in the monograph at §9 state what such a study would need to measure.
§1.4What this extract does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27181790
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. identifier not held by the Institute Cited by the Institute as an indicative analytical survey; sample frame was not random. The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.